Market research
PYC.AU PYC Therapeutics Limited
AU AUD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 3.798
- Dividend yield
- Not available
- Beta
- 1.08
Profile
Company facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- AU000000PYC7
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 3.798
- Dividend yield
- Not available
- Beta
- 1.08
About
About PYC Therapeutics Limited
PYC Therapeutics Limited, a clinical stage drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. It is developing PYC-003, which is in Phase1a/1b multiple ascending dose study for polycystic kidney disease; PYC-002, a Phelan McDermid Syndrome; PYC-001 for the treatment of Phelan-McDermid Syndrome; PYC-001, which is in Phase 1b multiple ascending dose study for autosomal dominant optic atrophy; and VP-001 for the treatment of retinitis pigmentosa type 11. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the PYC.AU discussion.
5 years, 5 months ago
PYC Therapeutics Limited is currently in a long term downtrend where the price is trading 1.8% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
PYC Therapeutics Limited's total revenue rose by 99.5% to $58K since the same quarter in the previous year.
Its net income has dropped by 250.8% to $-7M since the same quarter in the previous year.
Finally, its free cash flow fell by 237.3% to $-3M since the same quarter in the previous year.
Based on the above factors, PYC Therapeutics Limited gets an overall score of 2/5.